Source: International Congress 2018 – Pulmonary fibrosis: from models to patients
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Tsavlis (THESSALONIKI, Greece), D. Anestakis (THESSALONIKI, Greece), A. Tzoumaka (THESSALONIKI, Greece), C. Symeonidou (THESSALONIKI, Greece), K. Kouzi - Koliakou (THESSALONIKI, Greece), A. Tektonidou (THESSALONIKI, Greece), E. Spandou (THESSALONIKI, Greece). Erythropoietin (EPO) attenuates the immunohistochemical expression of tumor growth factor-ß (TGF-ß) in bleomycin (BLM)-induced pulmonary fibrosis (PF) in rats. 996

Member's Comments

No comment yet.

Related content which might interest you: Erythropoietin (EPO) attenuates the immunohistochemical expression of autophagy antibodies in bleomycin (BLM), induced pulmonary fibrosis (PF) in rats Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019 Erythropoietin (EPO) attenuates the expression of its receptor (EPO-R) in bleomycin (BLM)-induced pulmonary fibrosis (PF) in rats Source: Annual Congress 2012 - Fibrogenesis between epithelial injury and fibroblast proliferation Year: 2012 Erythropoietin (EPO) inhibits the bleomycin (BLM)-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Emerging mechanisms in lung injury Year: 2010 Erythropoietin (EPO) inhibits the immunohistochemical expression of lysyl oxidase (LOX) in bleomycin (BLM)-induced pulmonary fibrosis (PF) in rats Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 The effect of erythropoietin (EPO) on cyclooxygenase-2 (COX-2) and cytochrome-c (CYT-c) in the bleomycin (BLM)-induced pulmonary fibrosis (PF) in rats Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011 Hepatocyte growth factor (HGF) expression in bronchoveolar lower (BAL) does not confirm its anti-fibrotic activity in interstitial lung diseases (ILD) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 The attenuating effect of erythropoietin (EPO) on the expression of myeloperoxidase (MPO) in bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Broncholaveolar lavage (BAL) lymphocytes from patients with interstitial lung diseases (ILD) produce hepatocyte growth factor (HGF) Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009 Morphometric study of hypoxia inducible factor-1α-vascular endothelial growth factor (HIF-1α-VEGF) axis in patients with idiopathic pulmonary fibrosis with the use of tissue microarrays Source: Eur Respir J 2006; 28: Suppl. 50, 338s Year: 2006 Expression of insulin-growth factor-I (IGF-I) in alveolar lymphocytes (AL) in interstitial lung diseases (ILD). Potential functions of AL-derived IGF Source: Annual Congress 2005 - Progresses in lung fibrosis Year: 2005 Increased binding activity of hypoxia inducible factor (HIF)-1α to vascular endothelial growth factor (VEGF) promoter region mediates enhanced vascular permeability in the lung of cystic fibrosis (CF) patients Source: Eur Respir J 2003; 22: Suppl. 45, 173s Year: 2003 LATE-BREAKING ABSTRACT: Erythropoietin (EPO) inhibits the immunohistochemical expression of Tumor Necrosis Factor-a (TNF-a) in bleomycin (BLM)-induced pulmonary fibrosis (PF) in rats Source: International Congress 2014 – Lung cell biology in injury and repair Year: 2014 The neoadjuvant therapy of NSCLC down-regulates serum levels of growth factors (VEGF, bFGF, TGF-beta) with no effect on apoptosis (CD95L) and local tumour invasiveness markers (TIMP-1) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006 Connective tissue growth factor (CTGF) induces lung fibrosis in otherwise fibrosis-resistant Balb/c mouse in a bleomycin model Source: Eur Respir J 2004; 24: Suppl. 48, 104s Year: 2004 The influence of sera from interstitial lung diseases (ILD) patients on human mononuclear cells (MNC) production of vascular endothelial growth factor (VEGF) Source: Eur Respir J 2004; 24: Suppl. 48, 553s Year: 2004 Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control Source: International Congress 2016 – New findings in mucosal immunology Year: 2016 Down regulation of stromal cell-derived factor 1 (SDF-1/CXCL12) in lung tissue of patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 Keratinocyte growth factor (rHuKGF) increases surfactant protein A in rats and prevents alveolar oedema after orthotopic rat lung transplantation Source: Eur Respir J 2006; 28: Suppl. 50, 779s Year: 2006 Enhanced expression of interleukin 8 (CXCL8) in cystic fibrosis (CF) airway epithelial (AE) cells Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 Influence of recombinant human vascular endothelium growth factor- (rhVEGF-) 165 on surfactant proteins (SPs) mRNA levels in emphysematous rat lungs Source: Annual Congress 2008 - Structural remodelling in COPD Year: 2008